Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Article Pediatrics

Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure

Kinjal Desai et al.

Summary: This is a small study on the use of sildenafil in treating left-sided heart failure. The results show that sildenafil can improve heart function, but it needs to be titrated carefully with inpatient surveillance.

CHILDREN-BASEL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

Theresa A. McDonagh et al.

Summary: All experts involved in the development of the guidelines have declared their interests, and the declarations have been compiled and published in a supplementary report. The report can be accessed on the ESC website. The supplementary data provide background information and detailed discussion of the data that form the basis for the guidelines.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Review Medicine, General & Internal

Treatment of Hypertension: A Review

Robert M. Carey et al.

Summary: Hypertension, affecting approximately 116 million adults in the US and more than 1 billion adults worldwide, is a leading cause of cardiovascular disease morbidity and mortality. First-line therapy for hypertension involves lifestyle modifications such as weight loss, reduced sodium intake and increased potassium supplementation, healthy dietary patterns, physical activity, and limited alcohol consumption. When medication is necessary, first-line therapies include thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and calcium channel blockers.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Gerhard Hindricks et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

Patricia Palau et al.

Summary: This study aimed to evaluate the effect of beta-blocker withdrawal on peak oxygen consumption in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence. The results showed that beta-blocker withdrawal significantly improved maximal functional capacity in these patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Alice M. Jackson et al.

Summary: The study showed that sacubitril-valsartan may be effective in treating apparent resistant hypertension in patients with HFpEF, even in those who continue to have elevated blood pressure despite treatment with at least four antihypertensive drug classes, including an MRA.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Peripheral Vascular Disease

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

Alexandros Kasiakogias et al.

Summary: Hypertension is a major risk factor for HFpEF, and while specific guideline-directed medical therapy is not established, control of blood pressure is widely regarded as central to prevention and clinical care.

JOURNAL OF HYPERTENSION (2021)

Add to Collection

Article Peripheral Vascular Disease